Vita M Golubovskaya

Summary

Affiliation: Roswell Park Cancer Institute
Country: USA

Publications

  1. pmc Focal adhesion kinase as a cancer therapy target
    Vita M Golubovskaya
    Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Anticancer Agents Med Chem 10:735-41. 2010
  2. pmc MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells
    Vita M Golubovskaya
    Department of Surgical Oncology, Roswell Park, Cancer Institute, Buffalo, NY 14263, USA
    Anticancer Agents Med Chem 14:18-28. 2014
  3. pmc The microarray gene profiling analysis of glioblastoma cancer cells reveals genes affected by FAK inhibitor Y15 and combination of Y15 and temozolomide
    Grace Huang
    Department of Surgical Oncology Roswell Park Cancer Institute, Buffalo, NY, 14263, USA
    Anticancer Agents Med Chem 14:9-17. 2014
  4. pmc Focal adhesion kinase regulates expression of thioredoxin-interacting protein (TXNIP) in cancer cells
    Baotran Ho
    Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA
    Anticancer Agents Med Chem 14:3-8. 2014
  5. pmc FAK and Nanog cross talk with p53 in cancer stem cells
    Vita M Golubovskaya
    Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Anticancer Agents Med Chem 13:576-80. 2013
  6. pmc Mitoxantrone targets the ATP-binding site of FAK, binds the FAK kinase domain and decreases FAK, Pyk-2, c-Src, and IGF-1R in vitro kinase activities
    Vita M Golubovskaya
    Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Anticancer Agents Med Chem 13:546-54. 2013
  7. pmc A small-molecule inhibitor, 5'-O-tritylthymidine, targets FAK and Mdm-2 interaction, and blocks breast and colon tumorigenesis in vivo
    Vita M Golubovskaya
    Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Anticancer Agents Med Chem 13:532-45. 2013
  8. pmc A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonog
    Vita M Golubovskaya
    Department of Surgical Oncology, Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Carcinogenesis 33:1004-13. 2012
  9. pmc FAK overexpression and p53 mutations are highly correlated in human breast cancer
    Vita M Golubovskaya
    Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Int J Cancer 125:1735-8. 2009
  10. pmc Focal adhesion kinase and p53 signal transduction pathways in cancer
    Vita M Golubovskaya
    Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Front Biosci (Landmark Ed) 15:901-12. 2010

Collaborators

Detail Information

Publications22

  1. pmc Focal adhesion kinase as a cancer therapy target
    Vita M Golubovskaya
    Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Anticancer Agents Med Chem 10:735-41. 2010
    ..This review summarizes expression of FAK by immunohistochemical staining in different tumor types and presents several FAK inhibition therapy approaches...
  2. pmc MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells
    Vita M Golubovskaya
    Department of Surgical Oncology, Roswell Park, Cancer Institute, Buffalo, NY 14263, USA
    Anticancer Agents Med Chem 14:18-28. 2014
    ....
  3. pmc The microarray gene profiling analysis of glioblastoma cancer cells reveals genes affected by FAK inhibitor Y15 and combination of Y15 and temozolomide
    Grace Huang
    Department of Surgical Oncology Roswell Park Cancer Institute, Buffalo, NY, 14263, USA
    Anticancer Agents Med Chem 14:9-17. 2014
    ..Thus, microarray gene expression analysis can be effective in establishing genes affected in response to FAK inhibitor alone and in response to combination of Y15 with temozolomide that is important for glioblastoma therapy. ..
  4. pmc Focal adhesion kinase regulates expression of thioredoxin-interacting protein (TXNIP) in cancer cells
    Baotran Ho
    Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA
    Anticancer Agents Med Chem 14:3-8. 2014
    ..These results for the first time demonstrate FAK-regulated TXNIP expression which is important for apoptotic, survival and oxidative stress signaling pathways in cancer cells. ..
  5. pmc FAK and Nanog cross talk with p53 in cancer stem cells
    Vita M Golubovskaya
    Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Anticancer Agents Med Chem 13:576-80. 2013
    ..The cross-linked signaling of FAK with p53 and Nanog signaling in cancer stem cell and function and targeted therapeutics approaches are discussed...
  6. pmc Mitoxantrone targets the ATP-binding site of FAK, binds the FAK kinase domain and decreases FAK, Pyk-2, c-Src, and IGF-1R in vitro kinase activities
    Vita M Golubovskaya
    Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Anticancer Agents Med Chem 13:546-54. 2013
    ..Thus, this novel function of the mitoxantrone drug can be critical for future development of anti-cancer agents and FAK-targeted therapy research...
  7. pmc A small-molecule inhibitor, 5'-O-tritylthymidine, targets FAK and Mdm-2 interaction, and blocks breast and colon tumorigenesis in vivo
    Vita M Golubovskaya
    Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Anticancer Agents Med Chem 13:532-45. 2013
    ....
  8. pmc A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonog
    Vita M Golubovskaya
    Department of Surgical Oncology, Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Carcinogenesis 33:1004-13. 2012
    ..Thus, targeting the major autophosphorylation site of FAK with Y11 inhibitor is critical for development of cancer therapeutics and carcinogenesis field...
  9. pmc FAK overexpression and p53 mutations are highly correlated in human breast cancer
    Vita M Golubovskaya
    Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Int J Cancer 125:1735-8. 2009
    ..5, 95% CI 1.6-3.9]. This is the first analysis demonstrating a high correlation between FAK expression and p53 mutations in a population-based series of breast tumors...
  10. pmc Focal adhesion kinase and p53 signal transduction pathways in cancer
    Vita M Golubovskaya
    Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Front Biosci (Landmark Ed) 15:901-12. 2010
    ..found that N-myc binds FAK promoter and induces FAK transcription in neuroblastoma cells. Thus, this review will be focused on FAK and p53 signal transduction pathways in cancer...
  11. pmc FAK and p53 protein interactions
    Vita M Golubovskaya
    Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Anticancer Agents Med Chem 11:617-9. 2011
    ....
  12. pmc The direct effect of focal adhesion kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis
    Vita M Golubovskaya
    Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA
    BMC Cancer 9:280. 2009
    ..Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that plays an important role in survival signaling. FAK has been shown to be overexpressed in breast cancer tumors at early stages of tumorigenesis...
  13. pmc Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide
    Vita M Golubovskaya
    Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Mol Cancer Ther 12:162-72. 2013
    ....
  14. ncbi request reprint A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer
    Steven N Hochwald
    Department of Surgery, Roswell Park Cancer Institute, Buffalo, NY, USA
    Cell Cycle 8:2435-43. 2009
    ..Thus, targeting the Y397 site of FAK in pancreatic cancer with the small molecule inhibitor, 1,2,4,5-Benzenetetraamine tetrahydrochloride, is a potentially effective treatment strategy in this deadly disease...
  15. pmc FAK and HAS inhibition synergistically decrease colon cancer cell viability and affect expression of critical genes
    Melissa Heffler
    Department of Surgical Oncology, Roswell Park Cancer Institute and the University at Buffalo State University of New York, Buffalo, NY 14263, USA
    Anticancer Agents Med Chem 13:584-94. 2013
    ..Dual inhibition of FAK and HAS3 decreases viability to a greater degree than with either agent alone, and suggests that synergistic inhibition of colon cancer cell growth can result from affecting similar genetic pathways...
  16. pmc Vascular endothelial growth factor receptor-3 promotes breast cancer cell proliferation, motility and survival in vitro and tumor formation in vivo
    Elena V Kurenova
    Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Cell Cycle 8:2266-80. 2009
    ..For the first time, we have demonstrated that VEGFR-3 overexpression promotes breast cancer cell proliferation, motility, survival, anchorage-independent growth and tumorogenicity in the absence of ligand expression...
  17. pmc Nanog increases focal adhesion kinase (FAK) promoter activity and expression and directly binds to FAK protein to be phosphorylated
    Baotran Ho
    Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    J Biol Chem 287:18656-73. 2012
    ....
  18. pmc Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy
    Melissa Heffler
    Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY USA
    Cancer Biol Ther 14:761-72. 2013
    ..Thus, the small molecule FAK inhibitor, Y15, inhibits cell growth in vitro and in vivo and enhances the efficacy of chemotherapy, demonstrating that it can be an effective therapeutic inhibitor for treating colon cancer...
  19. pmc Inhibition of hyaluronan synthase-3 decreases subcutaneous colon cancer growth by increasing apoptosis
    Brian P Teng
    Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263 USA
    Anticancer Agents Med Chem 11:620-8. 2011
    ..HAS3 inhibition decreases subcutaneous tumor growth by colon cancer cells and significantly increases apoptosis with less effect on proliferation. These data show that HAS3 and HA mediate colon cancer growth by inhibiting apoptosis...
  20. pmc Targeting the p53 pathway
    Vita M Golubovskaya
    Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14127, USA CureFAKtor Pharmaceuticals, 14 Rock Dove Lane, Orchard Park, Buffalo, NY 1427, USA
    Surg Oncol Clin N Am 22:747-64. 2013
    ..This is a broad review of p53 function as it relates to the diagnosis and treatment of a wide range of cancers. ..
  21. pmc Evolving therapies and FAK inhibitors for the treatment of cancer
    Kelli Bullard Dunn
    Roswell Park Cancer Institute, University at Buffalo, State University of New York, NY, USA
    Anticancer Agents Med Chem 10:722-34. 2010
    ..This review summarizes the history and current use of targeted molecular therapy for cancer, with a special emphasis on recently developed inhibitors of Focal Adhesion Kinase (FAK)...
  22. ncbi request reprint The prognostic significance of focal adhesion kinase expression in stage I non-small-cell lung cancer
    Grace K Dy
    Department of Medicine Department of Pathology Department of Biostatistics and Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY
    J Thorac Oncol 9:1278-84. 2014
    ..Previous studies suggest that FAK overexpression is an independent factor predicting poor prognosis in non-small-cell lung cancer (NSCLC). The aim of this study is to confirm these findings specifically in stage I NSCLC...